The ongoing ARISE-HF Phase 3 global clinical trial is evaluating the safety and efficacy of AT-001 (caficrestat) in improving or preventing worsening of cardiac functional capacity in Diabetic Cardiomyopathy (DbCM); topline data from the study is expected.
Operator: Good day, ladies and gentlemen, and welcome to CymaBay’s First Quarter 2023 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
These 2 randomized clinical trials compare the efficacy and safety of 2 doses of the autotaxin inhibitor ziritaxestat vs placebo in patients with idiopathic pul
Dose proportionality and bioequivalence studies demonstrate once-daily AUSTEDO XR is therapeutically equivalent to twice-daily AUSTEDO® tablets
The U.S. Food and Drug Administration . | April 11, 2023